Cargando…

HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways

Measure of drug-mediated immune reactions that are dependent on the patient’s genotype determine individual medication protocols. Despite extensive clinical trials prior to the license of a specific drug, certain patient-specific immune reactions cannot be reliably predicted. The need for acknowledg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haukamp, Funmilola Josephine, Hartmann, Zoe Maria, Pich, Andreas, Kuhn, Joachim, Blasczyk, Rainer, Stieglitz, Florian, Bade-Döding, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000580/ https://www.ncbi.nlm.nih.gov/pubmed/36899812 http://dx.doi.org/10.3390/cells12050676

Ejemplares similares

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02
por: Simper, Gwendolin S., et al.
Publicado: (2018)

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects
por: Gall, Eline, et al.
Publicado: (2022)

HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

Markedly Elevated Carbamazepine-10,11-epoxide/Carbamazepine Ratio in a Fatal Carbamazepine Ingestion
por: Russell, Jason L., et al.
Publicado: (2015)

Deproteinization as a Rapid Method of Saliva Purification for the Determination of Carbamazepine and Carbamazepine-10,11 Epoxide
por: Dziurkowska, Ewelina, et al.
Publicado: (2020)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
por: Simper, Gwendolin S., et al.
Publicado: (2019)

The microstructure in the placenta is influenced by the functional diversity of HLA-G allelic variants
por: Stieglitz, F., et al.
Publicado: (2019)

The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infection
por: Abels, Wiebke C., et al.
Publicado: (2018)

HLA-F Allele-Specific Peptide Restriction Represents an Exceptional Proteomic Footprint
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

Polymorphic Phase Transitions in Carbamazepine and 10,11‐Dihydrocarbamazepine
por: Clout, Alexander E., et al.
Publicado: (2018)

HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children
por: Amstutz, Ursula, et al.
Publicado: (2013)

HLA-G peptide preferences change in transformed cells: impact on the binding motif
por: Celik, Alexander A., et al.
Publicado: (2018)

The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch
por: Celik, Alexander A., et al.
Publicado: (2015)

The HLA-A*31:01 allele: influence on carbamazepine treatment
por: Yip, Vincent Lai Ming, et al.
Publicado: (2017)

HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response—Implications on HSCT Outcome
por: Kraemer, Thomas, et al.
Publicado: (2015)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1
por: O'Connor, Geraldine M., et al.
Publicado: (2015)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01
por: Salzberger, Wilhelm, et al.
Publicado: (2015)

Soluble HLA Technology as a Strategy to Evaluate the Impact of HLA Mismatches
por: Kunze-Schumacher, Heike, et al.
Publicado: (2014)

Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes
por: Manandhar, Trishna, et al.
Publicado: (2016)

Distinct antibody profiles in HLA-B(∗)57(+), HLA-B(∗)57(−) HIV controllers and chronic progressors
por: Klingler, Jéromine, et al.
Publicado: (2022)

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity
por: Metushi, Imir G., et al.
Publicado: (2015)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
por: Martínez Buitrago, Ernesto, et al.
Publicado: (2019)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
por: Kolou, Malewe, et al.
Publicado: (2021)

SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients
por: Namazi, Soha, et al.
Publicado: (2015)

The Loss of HLA-F/KIR3DS1 Ligation Is Mediated by Hemoglobin Peptides
por: Hò, Gia-Gia T., et al.
Publicado: (2020)

HLA-E: A Novel Player for Histocompatibility
por: Kraemer, Thomas, et al.
Publicado: (2014)

Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
por: Brener, Jacqui, et al.
Publicado: (2018)

Improving turnaround times for HLA-B*27 and HLA-B*57:01 gene testing: a Barts Health NHS Trust quality improvement project
por: White, Emma, et al.
Publicado: (2021)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study
por: Van Den Driessche, George, et al.
Publicado: (2017)

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
por: Sooda, Anuradha, et al.
Publicado: (2022)

Pharmacogenomics Testing Confirmation of Carbamazepine Induced DRESS Reaction of an HLA-A*31:01 Positive, Polypharmacy Patient
por: Speicher, Leigh, et al.
Publicado: (2021)

HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese
por: Nguyen, Dinh Van, et al.
Publicado: (2015)

Identification of the novel HLA‐B*51:01:01:78 allele and confirmation of extended sequence of B*18:01:26
por: Ulrich, Silvia, et al.
Publicado: (2022)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

Muon capture by $^{10,11}$B nuclei: sensibility to the nuclear model choice
por: Kuzmin, V A, et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_d4gnk20lu2ter65os6tp8d1drm